Allergic Conjunctivitis: Clinical Trials

23 trials for Allergic Conjunctivitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 completed. 23 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 423Completed 23

Follow Allergic Conjunctivitis: new trials by email Literature Review of Allergic Conjunctivitis trials Research Report on Allergic Conjunctivitis

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction
NAAGA (N-acetyl-aspartyl-glutamate) 49 mg/mL, azelastine hydrochloride 0.05% - Allergic Conjunctivitis, Dry Eye Disease (DED)
Phase 4CompletedAzienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona1342023-04-212025-07-15
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis
olopatadine hydrochloride ophthalmic solution 0.7%), Fluticasone Propionate, Tears Naturale - Allergic Conjunctivitis
Phase 4CompletedAndover Research Eye Institute612021-12-312022-09-02
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale - Allergic Conjunctivitis
Phase 4CompletedAndover Research Eye Institute582021-12-142022-05-03
Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment
Bepotastine Besilate 1.5% PF, Olopatadine Hydrochloride 0.2% BAK - Allergic Conjunctivitis
Phase 4CompletedLaboratorios Poen972021-03-102022-12-15
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
Lastacaft ®, Tears Naturale ® (Placebo) - Allergic Conjunctivitis
Phase 4CompletedORA, Inc.252014-12-012021-03-18
Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
Olopatadine HCl ophthalmic solution, 0.1%, Epinastine HCl ophthalmic solution, 0.05% - Allergic Conjunctivitis
Phase 4CompletedAlcon Research502013-12-012015-10-07
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
Olopatadine hydrochloride ophthalmic solution, 0.2% - Allergic Conjunctivitis
Phase 4CompletedAlcon Research172012-09-012014-08-18
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution - Allergic Conjunctivitis
Phase 4CompletedORA, Inc.112012-01-012019-03-26
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
bepotastine besilate, 1.5%, Loteprednol etabonate - Allergic Conjunctivitis
Phase 4CompletedSouthern California College of Optometry at Marshall B. Ketchum University232011-10-012019-08-06
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
Fluticasone Propionate Nasal Spray, Saline Nasal Spray - Allergic Rhinitis, Allergic Conjunctivitis
Phase 4CompletedORA, Inc.222011-09-012021-04-14
The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer
Refresh Tears 0.5% Lubricant Eye Drops, Bepreve 1.5% Ophthalmic Solution - Allergic Conjunctivitis
Phase 4CompletedMinnesota Eye Consultants, P.A.402011-05-012020-03-31
A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis
Olopatadine Hydrochloride Ophthalmic Solution, 0.2% - Allergic Conjunctivitis
Phase 4CompletedAlcon Research3002011-05-012012-09-18
Assessment of Alcon's Ocular Image Quantification System
Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II) - Allergic Conjunctivitis
Phase 4CompletedAlcon Research132010-12-012012-12-18
Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients
NAABAK eyedrops, Saline eyedrops - Allergic Conjunctivitis
Phase 4CompletedLaboratoires Thea212010-10-012012-01-31
Patient Perception Study for AL-4943A
AL-4943A - Allergic Conjunctivitis
Phase 4CompletedAlcon Research472010-09-012016-12-16
Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis
Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®) - Allergic Conjunctivitis
Phase 4CompletedAlcon Research2152010-06-012012-04-03
Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients
Olopatadine hydrochloride ophthalmic solution 0.1% - Allergic Conjunctivitis
Phase 4CompletedAlcon Research422010-03-012015-05-12
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution, Inactive ingredients, used as placebo - Allergic Conjunctivitis
Phase 4CompletedAlcon Research1802010-03-012014-02-28
Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)
Olopatadine 0.1%, Tranilast 0.5%, Placebo (Olopatadine) - Allergic Conjunctivitis
Phase 4CompletedAlcon Research502008-07-012012-06-04
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Prednisolone Acetate 1%, Prednisolone Acetate 0.12%, Loteprednol Etabonate 0.2% - Allergic Conjunctivitis
Phase 4CompletedORA, Inc.362008-05-012020-09-02

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Conjunctivitis, Allergic (23)  ·  Conjunctivitis (4)  ·  Asthma (1)  ·  Dermatitis, Atopic (1)  ·  Dry Eye Syndromes (1)  ·  Rhinitis, Allergic (1)  ·  Rhinitis, Allergic, Seasonal (1)

Broader conditions

Conjunctival Diseases (23)  ·  Eye Diseases (23)  ·  Hypersensitivity (23)  ·  Hypersensitivity, Immediate (23)  ·  Immune System Diseases (23)  ·  Conjunctivitis (19)  ·  Nose Diseases (2)  ·  Otorhinolaryngologic Diseases (2)  ·  Respiratory Hypersensitivity (2)  ·  Respiratory Tract Diseases (2)  ·  Rhinitis (2)  ·  Bronchial Diseases (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Dermatitis (1)  ·  Genetic Diseases, Inborn (1)

Interventions

Olopatadine Hydrochloride (11)  ·  Lubricant Eye Drops (3)  ·  Ophthalmic Solutions (3)  ·  bepotastine besilate (3)  ·  Fluticasone (2)  ·  Loteprednol Etabonate (2)  ·  Dexamethasone (1)  ·  Dextrans (1)  ·  Hypromellose Derivatives (1)  ·  Loratadine (1)  ·  Methylprednisolone (1)  ·  alcaftadine (1)  ·  epinastine (1)  ·  isospaglumic acid (1)  ·  montelukast (1)

Sponsors

Alcon Research (10)  ·  ORA, Inc. (4)  ·  Andover Research Eye Institute (2)  ·  Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona (1)  ·  Laboratoires Thea (1)  ·  Laboratorios Poen (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Minnesota Eye Consultants, P.A. (1)  ·  Southern California College of Optometry at Marshall B. Ketchum University (1)  ·  University of Helsinki (1)

Countries

United States (11)  ·  Italy (2)  ·  South Korea (2)  ·  Argentina (1)  ·  Finland (1)  ·  India (1)  ·  Japan (1)

Top investigators

Tarek Shazly, MD (2)  ·  Ahmad M Fahmy, O.D. (1)  ·  Christine Sindt, OD, FAAO (1)  ·  Eriko Chono (1)  ·  Gail L Torkildsen, MD (1)  ·  Judy Tong, OD (1)  ·  Mario Troisi, MD (1)  ·  Michael Raizman, MD (1)  ·  Pam Kaur, MS PhD (1)  ·  Tari Haahtela, Professor (1)  ·  Terry Wiernas (1)  ·  Tsunemitsu Senta (1)

Results publications

PMID 19127072